Premium priced placement raises up to A$0.5 million; transaction update

Non-brokered private placement to strategic investor strengthens AdAlta’s ability to close cellular immunotherapy transactions

• AdAlta has received a firm commitment to raise A$0.5 million from a new Hong Kong based sophisticated investor (subject to shareholder approval in respect to part), vis a non-brokered private placement

• Issue Price of 0.3c per share ($0.003) represents a 20% premium to closing price on 10 October

• Company will issue Subscription Shares under and Attaching Options on the same terms as the recent fully subscribed Entitlement Offer

• Proceeds to strengthen AdAlta’s position as it advances “East to West” cellular immunotherapy transactions and other strategic options